Hutchmed To Announce 2026 Half: Year Results

HUTCHMED (China)

30/06/2026 09:30

RNS Number : 2351K
  
Hutchmed (China) Limited
  
30 June 2026
  
 


HUTCHMED to Announce 2026 Half-Year Financial Results
 
Hong Kong, Shanghai & Florham Park, NJ - Tuesday, June 30, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
 
HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).
 
Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
 
About HUTCHMED
 
HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
 
 
CONTACTS
 




Investor Enquiries


+852 2121 8200 / ir@hutch-med.com














Media Enquiries








FTI Consulting -


+44 20 3727 1030 / HUTCHMED@fticonsulting.com




   Ben Atwell / Tim Stamper


   +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)




Brunswick - Zhou Yi


+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com














Panmure Liberum


Nominated Advisor and Joint Broker




Atholl Tweedie / Emma Earl / Rupert Dearden


+44 20 7886 2500














Cavendish


Joint Broker




Geoff Nash / Nigel Birks


+44 20 7220 0500














Deutsche Numis


Joint Broker




Duncan Monteith / Ramin Naji


+44 20 7545 8000




 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NORUKUVRNUUNUAR